Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Détails
Télécharger: Thiebaut et al_Autophagy_2022.pdf (6262.66 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: CC BY 4.0
Etat: Public
Version: Author's accepted manuscript
Licence: CC BY 4.0
ID Serval
serval:BIB_92B2E7EE737F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Périodique
Autophagy
ISSN
1554-8635 (Electronic)
ISSN-L
1554-8627
Statut éditorial
Publié
Date de publication
06/2022
Peer-reviewed
Oui
Volume
18
Numéro
6
Pages
1297-1317
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Cerebral ischemia is a pathology involving a cascade of cellular mechanisms, leading to the deregulation of proteostasis, including macroautophagy/autophagy, and finally to neuronal death. If it is now accepted that cerebral ischemia induces autophagy, the effect of thrombolysis/energy recovery on proteostasis remains unknown. Here, we investigated the effect of thrombolysis by PLAT/tPA (plasminogen activator, tissue) on autophagy and neuronal death. In two in vitro models of hypoxia reperfusion and an in vivo model of thromboembolic stroke with thrombolysis by PLAT/tPA, we found that ischemia enhances neuronal deleterious autophagy. Interestingly, PLAT/tPA decreases autophagy to mediate neuroprotection by modulating the PI3K-AKT-MTOR pathways both in vitro and in vivo. We identified IGF1R (insulin-like growth factor I receptor; a tyrosine kinase receptor) as the effective receptor and showed in vitro, in vivo and in human stroke patients and that PLAT/tPA is able to degrade IGFBP3 (insulin-like growth factor binding protein 3) to increase IGF1 (insulin-like growth factor 1) bioavailability and thus IGF1R activation.Abbreviations: AKT/protein kinase B: thymoma viral proto-oncogene 1; EGFR: epidermal growth factor receptor; Hx: hypoxia; IGF1: insulin-like growth factor 1; IGF1R: insulin-like growth factor I receptor; IGFBP3: insulin-like growth factor binding protein 3; Ka: Kainate; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MAPK/ERK: mitogen-activated protein kinase; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; OGD: oxygen and glucose deprivation; OGD <sub>reox</sub> : oxygen and glucose deprivation + reoxygentation; PepA: pepstatin A1; PI3K: phosphoinositide 3-kinase; PLAT/tPA: plasminogen activator, tissue; PPP: picropodophyllin; SCH77: SCH772984; ULK1: unc-51 like kinase 1; Wort: wortmannin.
Mots-clé
Autophagy, Brain Ischemia/drug therapy, Glucose/pharmacology, Humans, Hypoxia, Insulin-Like Growth Factor Binding Protein 3/metabolism, Insulin-Like Growth Factor Binding Protein 3/pharmacology, Insulin-Like Growth Factor I/metabolism, Mechanistic Target of Rapamycin Complex 1/metabolism, Oxygen/pharmacology, Phosphatidylinositol 3-Kinases/metabolism, Proto-Oncogene Proteins c-akt/metabolism, Signal Transduction, Stroke/drug therapy, TOR Serine-Threonine Kinases/metabolism, Thrombolytic Therapy, Tissue Plasminogen Activator/metabolism, Tissue Plasminogen Activator/pharmacology, IGF1R, IGFBP3, LC3, MTORC1, SQSTM1/p62, stroke
Pubmed
Web of science
Financement(s)
Fonds national suisse / Projets / 310030-182332
Fonds national suisse / Projets / 310030-163064
Création de la notice
15/09/2021 14:32
Dernière modification de la notice
11/02/2023 7:13